NEW YORK, March 29, 2017 /PRNewswire/ -- The federal multidistrict litigation established for Taxotere lawsuits involving allegations of permanent alopecia is continuing to progress in the U.S. District Court, Eastern District of Louisiana. According to a Pretrial Order issued on March 27th, the Court will convene Science Day on May 3, 2017 at 8:30 a.m., CST. At that time, the parties will have the opportunity to apprise the Court of the medical and scientific issues central to the Taxotere litigation. (In Re: Taxotere (Docetaxal) Products Liability Litigation - MDL No. 2740)
"It is not unusual for multidistrict litigations or other centralized proceedings to convene Science Days. As stipulated by the Court's Order, the presentations made by the parties during these events are educational, rather than adversarial, in nature," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is now offering free case reviews to breast cancer patients and others whose hair failed to grow back following chemotherapy with Taxotere.
Taxotere was brought to market by Sanofi-Aventis in 1996, and was initially indicated to treat breast cancer. Since then, the U.S. Food & Drug Administration has expanded its approved uses to include head and neck cancer, gastric cancer, prostate cancer and non-small cell lung cancer. In December 2015 – nearly two decades after the drug came on the market - Sanofi-Aventis modified Taxotere's U.S label to note that it had been associated with reports of permanent hair loss.
Nearly 800 Taxotere lawsuits are pending in the Eastern District of Louisiana. Plaintiffs acknowledge that alopecia is a common side effect of chemotherapy. However, they assert that hair loss associated with Taxotere is more likely to be permanent compared to alternative, equally effective chemotherapy agents. While Sanofi did provide information regarding the potential for permanent alopecia to individual patients and regulatory agencies overseas, Taxotere plaintiffs claim that the U.S. label only included a generic, vague, and insufficient warning that "hair generally grows back"
Taxotere patients may be entitled to compensation if they experienced permanent alopecia following treatment. To learn more about filing a Taxotere lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/court-overseeing-federal-taxotere-hair-loss-lawsuits-to-convene-science-day-in-may-bernstein-liebhard-llp-reports-300431199.html
SOURCE Bernstein Liebhard LLP